Molecular Profiling to Inform Treatment Decisions for Patients With NSCLC

Giorgio V. Scagliotti, MD

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non—small cell lung cancer (NSCLC).

The use of next-generation sequencing (NGS), which involes a number of available platforms, is more than a clinical exercise, Scagliotti says. This is especially true in lung cancer, an area where a few oncogenic drivers can be targeted in clinical practice.

Clinicians can also request testing for a limited number of genes, which is what is recommended in the 2018 College of American Pathologists (CAP) guidelines. These recommend testing forEGFRmutations, including T790M,ALKtranslocations,ROS1fusions, andBRAFmutations.RETfusions are still a matter of research and are extremely rare, he adds.